慢性粒细胞白血病 中国就医指南

Chronic Myeloid Leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the uncontrolled proliferation of myeloid lineage cells—particularly granulocytes—in the bone marrow and peripheral blood. It is defined molecularly by the presence of the Philadelphia chromosome (Ph+), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)], which generates the BCR-ABL1 fusion oncogene. This chimeric gene encodes a constitutively active tyrosine kinase that drives aberrant cell survival, proliferation, and impaired apoptosis—fundamental hallmarks of CML pathogenesis. CML typically progresses through three clinical phases: chronic phase (CP), accelerated phase (AP), and blast phase (BP); most patients are diagnosed in CP, where symptoms are often subtle or absent. Epidemiologically, CML accounts for approximately 15% of adult leukemias in Western populations, with an annual incidence of 1–2 cases per 100,000 individuals. It predominantly affects adults, with a median age at diagnosis of 64 years; pediatric cases are rare (<5% of all CML). No strong environmental or lifestyle risk factors have been consistently identified—unlike many cancers, CML is not linked to smoking, diet, or occupational exposures. Ionizing radiation remains the only well-established risk factor, notably observed in atomic bomb survivors. The disease’s chronic nature and lifelong treatment requirements significantly impact quality of life: patients may experience persistent fatigue, early satiety (due to splenomegaly), night sweats, weight loss, and anxiety related to treatment adherence, monitoring burden (e.g., monthly PCR testing), and fear of progression or resistance. While modern tyrosine kinase inhibitors (TKIs)—such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib—have transformed CML into a manageable chronic condition with near-normal life expectancy for most CP patients, long-term toxicities (e.g., cardiovascular events, pleural effusions, metabolic disturbances) and financial strain from prolonged therapy remain critical concerns. Psychosocial support, patient education, and integrated care models are increasingly emphasized to preserve functional status and emotional well-being throughout decades of treatment.

# 慢性粒细胞白血病（CML）治疗方案与费用明细（血液科）

一、非手术/药物治疗（一线标准方案）

• •适用人群：初诊慢性期患者，Ph染色体/BCR-ABL1阳性
• •TKI药物方案（按档次分）：

- 二代达沙替尼/尼洛替尼（原研）：24,000–36,000元/年（含每3月骨髓象+融合基因检测：1,200–1,800元/次） - 三代博舒替尼（耐药或不耐受者）：45,000–60,000元/年

二、根治性治疗（异基因造血干细胞移植）

• •适用人群：加速/急变期、T315I突变、二代TKI治疗失败、年轻（≤55岁）、有HLA相合供者
• •全套费用区间：350,000–650,000元（含预处理化疗、移植术、住院监护、抗排异及感染防治）
• •术前检查费（必查）：HLA配型（2,800元）、供者筛查（4,500元）、心肺功能及病毒学全套（3,200元）

三、特殊复杂情况处理

• •T315I耐药：普纳替尼（医保谈判后）18,000–22,000元/月；或联合奥雷巴替尼（国产）15,000–19,000元/月
• •急变期转化：强化疗+桥接移植，单周期诱导化疗（阿糖胞苷+伊达比星）12,000–18,000元

四、方案快速选择指南

• •预算有限/初治慢性期 → 国产伊马替尼 + 定期PCR监测
• •追求深度缓解/年轻患者 → 尼洛替尼原研 + 严格分子学监测
• •TKI耐药/急变期 → 全面评估后启动移植或三代TKI联合临床试验